Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Study of the Administration of T Lymphocytes Expressing the Kappa Chimeric Antigen Receptor (CAR) and CD28 Endodomain for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

NCT04223765 is registered in ClinicalTrials.gov with UNC Lineberger Comprehensive Cancer Center as lead sponsor.

NCT NCT04223765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04223765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Study of the Administration of T Lymphocytes Expressing the Kappa Chimeric Antigen Receptor (CAR) and CD28 Endodomain for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Phase
Phase 1
Overall status
Recruiting
Start date
November 12, 2020
Completion date
March 22, 2043
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue, follicular lymphoma, indolent non-hodgkin lymphoma, mantle cell lymphoma, nodal marginal zone lymphoma, splenic marginal zone lymphoma